Haploidentical stem cell transplantation with posttransplant cyclophosphamide for refractory systemic juvenile xanthogranuloma

Jumpei Ito, Haruko Shima, Kyohei Inoue, Fumito Yamazaki, Hiroyuki Shimada

Research output: Contribution to journalArticle

Abstract

Juvenile xanthogranuloma (JXG) is a generally benign, self-limited histiocytic disorder, which belongs to non-Langerhans cell histiocytoses (non-LCH). However, systemic JXG can be fatal in rare cases. We present the case of an 11-year-old female with systemic JXG, who experienced repeated vertebral compression fractures and did not fully respond to systemic chemotherapy. Based on its reported efficacy in LCH, the patient underwent human leukocyte antigen-haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide. The patient did not suffer major complications and has not experienced relapse for 13 months since HSCT. HSCT may be a potential treatment option for patients with refractory non-LCH.

Original languageEnglish
Article numbere27926
JournalPediatric Blood and Cancer
Volume66
Issue number10
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Juvenile Xanthogranuloma
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Non-Langerhans-Cell Histiocytosis
Cyclophosphamide
Compression Fractures
HLA Antigens
Recurrence
Drug Therapy
Therapeutics

Keywords

  • allogeneic hematopoietic stem cell transplantation
  • haploidentical HSCT with posttransplant cyclophosphamide
  • juvenile xanthogranuloma
  • non-LCH

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{6d66fd89d09b40d68e517935ddeac680,
title = "Haploidentical stem cell transplantation with posttransplant cyclophosphamide for refractory systemic juvenile xanthogranuloma",
abstract = "Juvenile xanthogranuloma (JXG) is a generally benign, self-limited histiocytic disorder, which belongs to non-Langerhans cell histiocytoses (non-LCH). However, systemic JXG can be fatal in rare cases. We present the case of an 11-year-old female with systemic JXG, who experienced repeated vertebral compression fractures and did not fully respond to systemic chemotherapy. Based on its reported efficacy in LCH, the patient underwent human leukocyte antigen-haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide. The patient did not suffer major complications and has not experienced relapse for 13 months since HSCT. HSCT may be a potential treatment option for patients with refractory non-LCH.",
keywords = "allogeneic hematopoietic stem cell transplantation, haploidentical HSCT with posttransplant cyclophosphamide, juvenile xanthogranuloma, non-LCH",
author = "Jumpei Ito and Haruko Shima and Kyohei Inoue and Fumito Yamazaki and Hiroyuki Shimada",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/pbc.27926",
language = "English",
volume = "66",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Haploidentical stem cell transplantation with posttransplant cyclophosphamide for refractory systemic juvenile xanthogranuloma

AU - Ito, Jumpei

AU - Shima, Haruko

AU - Inoue, Kyohei

AU - Yamazaki, Fumito

AU - Shimada, Hiroyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Juvenile xanthogranuloma (JXG) is a generally benign, self-limited histiocytic disorder, which belongs to non-Langerhans cell histiocytoses (non-LCH). However, systemic JXG can be fatal in rare cases. We present the case of an 11-year-old female with systemic JXG, who experienced repeated vertebral compression fractures and did not fully respond to systemic chemotherapy. Based on its reported efficacy in LCH, the patient underwent human leukocyte antigen-haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide. The patient did not suffer major complications and has not experienced relapse for 13 months since HSCT. HSCT may be a potential treatment option for patients with refractory non-LCH.

AB - Juvenile xanthogranuloma (JXG) is a generally benign, self-limited histiocytic disorder, which belongs to non-Langerhans cell histiocytoses (non-LCH). However, systemic JXG can be fatal in rare cases. We present the case of an 11-year-old female with systemic JXG, who experienced repeated vertebral compression fractures and did not fully respond to systemic chemotherapy. Based on its reported efficacy in LCH, the patient underwent human leukocyte antigen-haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide. The patient did not suffer major complications and has not experienced relapse for 13 months since HSCT. HSCT may be a potential treatment option for patients with refractory non-LCH.

KW - allogeneic hematopoietic stem cell transplantation

KW - haploidentical HSCT with posttransplant cyclophosphamide

KW - juvenile xanthogranuloma

KW - non-LCH

UR - http://www.scopus.com/inward/record.url?scp=85071060589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071060589&partnerID=8YFLogxK

U2 - 10.1002/pbc.27926

DO - 10.1002/pbc.27926

M3 - Article

C2 - 31309704

AN - SCOPUS:85071060589

VL - 66

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

M1 - e27926

ER -